je.st
news
Tag: cancer
Mercks KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
2016-08-02 23:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
express
cell
approved
PPG Completes First COLORFUL COMMUNITIES Project in Brazil at Children\'s Cancer Institute
2016-07-20 14:51:00| Coatings World Breaking News
Tags: project
institute
brazil
communities
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA (pembrolizumab) for the Treatment of Multiple Types of Cancer
2016-06-29 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & CAMBRIDGE, Mass. Collaboration Combines Mercks Leadership in Immuno-Oncology with Modernas Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879or Moderna Media:Liz Melone, 617-256-6622orInvestors:Maren Winnick, 617-674-5297 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
types
multiple
treatment
Pulling apart poor research linking alcohol consumption and cancer - International Scientific Forum on Alcohol Research Critique 188
2016-06-28 14:04:46| Daily beverage news and comment - from just-drinks.com
Previous scientific research has shown that heavy alcohol consumption is a major risk factor for upper aero-digestive cancers, and even light drinking increases slightly the risk of breast cancer in women. A recent study is based on a very small number of cases of cancer in New Zealand, tabulated separately for Maori and non-Maori subjects. The research applies estimates of alcohol effects from other population-based studies.
Tags: forum
international
research
poor
Merck Receives CHMP Positive Opinion for KEYTRUDA (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
2016-06-27 12:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
positive
cell
opinion
Sites : [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] next »